Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Marinus Pharmaceuticals, Inc. - Common Stock (NQ:MRNS)

0.5500 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Marinus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Analyst Ratings for Marinus Pharma ↗
 
Via Benzinga
News headline image
Analyst Ratings for Marinus Pharma ↗
 
Via Benzinga
News headline image
Earnings Preview: Marinus Pharma ↗
 
Via Benzinga
News headline image
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Analyst Expectations for Marinus Pharma's Future ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Marinus Pharma ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy. 
Via Benzinga
Topics Bankruptcy
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023 ↗
 
Via Benzinga
News headline image
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Earnings Scheduled For August 10, 2023 ↗
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
News headline image
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Marinus Pharmaceuticals Announces New Method of Use Patent Granted for IV Ganaxolone by USPTO in Status Epilepticus
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers GSI Technology, Inc. (NASDAQ: GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial results for its fiscal fourth quarter after the market close on May 16,... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.